现代医药卫生2025，Vol.41Issue(6)：1327-1330,4.DOI:10.3969/j.issn.1009-5519.2025.06.008
替雷利珠单抗治疗肝癌的临床研究
Clinical study of tirelizumab in the treatment of liver cancer
摘要
Abstract
Objective To analyze the occurrence of adverse drug reactions(ADR)and related influen-cing factors in the treatment of liver cancer with tislelizumab in a certain hospital.Methods A total of 650 medical records and ADR data from patients who received tislelizumab between January 2022 and January 2024 were collected.At the same time,the usage data and ADR data of other monoclonal antibodies which were also programmed death receptor-1(PD-1)inhibitors were collected.The incidence of ADR in patients with liver cancer with different characteristics treated with tislelizumab was compared.Results A total of 650 patients with liver cancer were treated with monoclonal antibody,of which 480 cases were treated with tisleli-zumab,accounting for 73.85%;170 cases were treated with other monoclonal antibodies,accounting for 26.15%.Among 480 patients with liver cancer treated with tislelizumab,6 patients developed ADR,the inci-dence was 1.25%.The incidence of ADR in the treatment of liver cancer with tislelizumab was lower than that with carrelizumab,and the difference was not statistically significant(P=0.420).There was no significant difference in the incidence of ADR among liver cancer patients with different gender,age,smoking history,drinking history,concomitant hypertension,concomitant coronary heart disease and concomitant diabetes mel-litus(P>0.05).There was significant difference in the incidence of ADR among liver cancer patients with dif-ferent body mass index(BMI)treated with tislelizumab(P<0.05).There was no significant difference in the incidence of ADR among liver cancer patients with different gender,age,smoking history and drinking history treated with tislelizumab and carrelizumab(P>0.05).There was significant difference in the incidence of ADR among patients with liver cancer complicated with hypertension treated with tislelizumab and carreli-zumab(P<0.05).Conclusion The incidence of ADR in the treatment of liver cancer with tislelizumab is low,and BMI and concomitant hypertension are the potential influencing factors of ADR.关键词
替雷利珠单抗/抑制剂/肝癌/药品不良反应Key words
Tislelizumab/Inhibitor/Liver cancer/Adverse drug reactions分类
临床医学引用本文复制引用
陈玲园,石梅,李晓文,覃俊艳,张发恩,韦亚娜,梁方林..替雷利珠单抗治疗肝癌的临床研究[J].现代医药卫生,2025,41(6):1327-1330,4.基金项目
广西壮族自治区药品安全科研项目(桂药监科直属[2023]010号). （桂药监科直属[2023]010号）
